Usually, these cells are collected from tumor biopsies or the patient’s blood, and can be enriched for tumor-reactive clones by sorting for CD137, CD39 and PD-1 positivity, in order to increase yield [62,63,64,65]. Here, TNFRSF9 is linked to neoplasm.